Exelixis

EXELNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$14.409 B

$58.15 +1.63%

Close of 22 Sept 2026

Revenue

$2.32B

#1060 by revenue

Earnings

$782.6M

#468 by earnings

Shares outstanding

247,781,692

Latest filing cover page

P/E ratio

18.4

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#7BioNTech SEBNTX$25.3B
#8Neurocrine BiosciencesNBIX$14.5B
#9ExelixisEXEL$14.4B
#10Halozyme TherapeuticsHALO$13.1B
#11Bio-TechneTECH$11.4B

What if Exelixis were worth as much as…

Open the what-if tool →

Gold $30.2T

$122,018.58

Per share 2,098× higher

Bitcoin $1.74T

$7,028.99

Per share 121× higher

Nvidia $5.52T

$22,260.59

Per share 383× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Exelixis are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.